JP7382085B2 - Joint function improvement composition - Google Patents

Description

The present invention relates to a composition capable of improving joint function, and more particularly to a composition containing glucosamine and certain other ingredients as active ingredients.

As the population ages, the number of people suffering from joint pain such as knee and elbow pain is increasing, and there is a desire for pharmaceuticals and the like that can relieve such joint pain. For example, amino sugars such as glucosamine are attracting attention as materials that are effective in improving arthritis, which is one of the causes of joint pain (see Patent Document 1).

Japanese Patent Application Publication No. 2003-325136

An object of the present invention is to provide a composition that can protect cartilage and improve joint function.

In order to improve joint function, the present inventors conducted intensive investigation and research into the cartilage present in joints, and discovered that a combination of glucosamine and certain other components can provide a high cartilage protection effect. , we have completed the present invention. That is, the inventors have discovered that cartilage can be more effectively protected by combining glucosamine with certain other components that have little or no chondroprotective ability.

That is, the present invention relates to a composition containing glucosamine and at least one component selected from the group consisting of (a) to (f) below as active ingredients.
(a) At least one plant material selected from barley, Chomeiso, Kudzu, rice, Maqui berry, and ginger (b) At least one functional additive selected from aspartame, sucrose fatty acid ester, and calcium stearate ( c) At least one amino acid selected from alanine, asparagine, glutamic acid, histidine, isoleucine, leucine, phenylalanine, proline, serine, tyrosine, valine, and S-adenosylmethionine (d) selected from gallic acid and chlorogenic acid At least one type of polyphenol (e) At least one type selected from vitamin A, vitamin B1, vitamin B2, vitamin B12, vitamin C, vitamin D3, sodium pantothenate, niacin, biotin, vitamin K, β-carotene, calcium, and selenium. (f) At least one cartilage component selected from proteoglycans and type II collagen.

The composition of the present invention can be used as a joint function improving agent that has a cartilage protective effect.

The composition of the present invention may be obtained by adding an active ingredient consisting of glucosamine and at least one ingredient selected from the group consisting of (a) to (f).

Further, the composition of the present invention is preferably for oral use, and is preferably in the form of a tablet, capsule, powder, granule, or liquid.

The present invention also relates to a method for improving joint function (excluding medical treatment), which comprises ingesting the composition of the present invention.

According to the composition of the present invention, cartilage can be protected and joint function can be improved.

It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + plant material) is applied to chondrocytes (NHAc-kn), the upper left diagram shows that using barley as the plant material, and the upper right diagram shows the one using long life grass as the plant material, the lower left figure shows the one using kudzu as the plant material, and the lower right figure shows the one using rice (rice bran) as the plant material. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + plant material) is applied to chondrocytes (NHAc-kn), the upper left diagram shows that using maqui berry as the plant material, and the upper right diagram shows the one using red ginger (Zingiber officinale var. Rubra) as the plant material, and the lower left figure shows the one using ginger (Zingiber officinale) as the plant material. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + functional additive) is applied to chondrocytes (NHAc-kn), and the upper left diagram shows the expression level of MMP3 when the composition of the present invention (glucosamine + functional additive) is applied to chondrocytes (NHAc-kn). The upper right figure shows the one using sucrose fatty acid ester as the functional additive, and the lower left figure shows the one using calcium stearate as the functional additive. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + amino acid) is applied to chondrocytes (NHAc-kn), the upper left diagram shows the one using alanine as the amino acid, and the upper right diagram shows the amino acid. The lower left diagram shows the one using asparagine as the amino acid, the lower left diagram shows the one using glutamic acid as the amino acid, and the lower right diagram shows the one using histidine as the amino acid. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + amino acid) is applied to chondrocytes (NHAc-kn), the upper left diagram shows the one using isoleucine as the amino acid, and the upper right diagram shows the amino acid. The lower left diagram shows the one using leucine as the amino acid, the lower left diagram shows the one using phenylalanine as the amino acid, and the lower right diagram shows the one using proline as the amino acid. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + amino acid) is applied to chondrocytes (NHAc-kn), the upper left diagram shows the one using serine as the amino acid, and the upper right diagram shows the amino acid. The lower left diagram shows the one using tyrosine as the amino acid, the lower left diagram shows the one using valine as the amino acid, and the lower right diagram shows the one using S-adenosylmethionine (SAMe) as the amino acid. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + polyphenol) is applied to chondrocytes (NHAc-kn), the left diagram shows that using gallic acid as the polyphenol, and the right diagram This shows the use of chlorogenic acid as the polyphenol. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to chondrocytes (NHAc-kn), and the upper left diagram shows the one using vitamin A as the vitamin. The upper right figure shows the one using vitamin B1 as the vitamin, the lower left figure shows the one using vitamin B2 as the vitamin, and the lower right figure shows the one using vitamin B12 as the vitamin. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to chondrocytes (NHAc-kn), and the upper left diagram shows the one using vitamin C as the vitamin. The upper right figure shows the one using vitamin D3 as the vitamin, the lower left figure shows the one using sodium pantothenate as the vitamin, and the lower right figure shows the one using niacin as the vitamin. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to chondrocytes (NHAc-kn), the upper left diagram shows the one using biotin as vitamins, The upper right diagram shows the one using vitamin K as the vitamin, and the lower left diagram shows the one using β-carotene as the vitamin. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to cartilage cells (NHAc-kn), and the upper left diagram shows the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to cartilage cells (NHAc-kn). The upper right figure shows the one using shell calcined Ca as the minerals, the lower left figure shows the one using shell uncalcined Ca as the minerals, and the lower right figure shows the one using milk Ca as the minerals. FIG. 2 is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + vitamins and minerals) is applied to chondrocytes (NHAc-kn), using selenium as the mineral. It is a diagram showing the expression level of MMP3 when the composition of the present invention (glucosamine + cartilage component) is applied to chondrocytes (NHAc-kn), the left diagram shows the one using proteoglycan as the cartilage component, and the right diagram shows one using type II collagen as the cartilage component.

The composition of the present invention is characterized by containing glucosamine and at least one component selected from the group consisting of (a) to (f) below (hereinafter sometimes referred to as other components) as active ingredients. do. The following components (a) to (f) used together with glucosamine may be used alone (for example, component (a)) or in combination of two or more. When using a combination of two or more other ingredients, it is preferable to combine other ingredients that have a high synergistic effect with glucosamine.

The composition of the present invention (composition for improving joint function) can protect cartilage by suppressing the destruction of chondrocytes, improve joint pain more effectively (including prevention), and improve joint function. It can be used as a joint function improving agent because it can be used to its full potential. Furthermore, the composition for improving joint function of the present invention can protect cartilage throughout the body and improve joint pain throughout the body, but it can particularly protect cartilage in the lower back, hip joints, and knee joints, thereby improving pain in such areas. This can improve joint function.

[Glucosamine]
As the glucosamine of the present invention, glucosamine and its salts, and N-acetylglucosamine can be used. Examples of the salt include hydrochloride, sulfate, phosphate and the like. Such glucosamine may be of biological origin or may be chemically synthesized.

[Other ingredients]
(a) Plant material In the joint function improving composition of the present invention, it is preferable to use at least one plant material selected from barley, chomeiso, kudzu, rice, maqui berry, and ginger as an active ingredient together with glucosamine. .

These plant materials may be any part of the plant, such as leaves, stems, roots, flowers, fruits, trunks, branches, etc., and may include the plant materials themselves (including dried materials), crushed products, and squeezed juice. , extracts, and other processed plant materials can be used. Examples of the pulverized product include powder, granules, and the like. The squeezed juice or extract may be in liquid form, but it can also be used in the form of a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water (hot water), ethanol, and aqueous ethanol. Commercially available plant materials can be used as these plant materials.

As the barley, two-row barley, six-row barley, etc. can be used. The parts used as the plant material of the present invention are preferably stems and leaves, with young leaves being particularly preferred.

Chomeiso is a perennial plant also called Botanbofuu that belongs to the Apiaceae family. The parts used as the plant material of the present invention are preferably leaves and roots.

Kudzu is a climbing perennial plant belonging to the Fabaceae family and the genus Kudzu. The parts used as the plant material of the present invention are preferably flowers and roots, and flowers are particularly preferred. Kudzu flowers may be collected at any stage from buds to fully opened flowers, or a mixture of kudzu flowers collected at each stage may be used. The type of kudzu is not particularly limited, but examples include Pueraria thomsonii, Pueraria lobata, and Pueraria thunbergiana.

Rice is a plant belonging to the Poaceae family, Poaceae. The parts used as the plant material of the present invention are preferably brown rice rinds and embryos, and specifically, it is preferable to use rice bran obtained as a by-product when milling brown rice. There are no particular restrictions on the type of rice, and examples include japonica and indica.

Maqui berry is a plant of the Portonaceae family that is native to Patagonia, Chile, and its scientific name is Aristotelia chilensis. The part used as the plant material of the present invention is preferably a fruit.

Ginger is a plant belonging to the Zingiberaceae family and genus Zingiber, and includes, for example, Sanshu ginger and Yellow ginger whose scientific name is Zingiber officinale. Furthermore, red ginger (local name: Jahe merah), whose scientific name is Zingiber officinale var. Rubra and which is cultivated in Indonesia and India, can also be preferably used. As the part used as the plant material of the present invention, rhizomes are preferable.

(b) Functional additive In the joint function improving composition of the present invention, at least one functional additive selected from aspartame, sucrose fatty acid ester, and calcium stearate may be used as an active ingredient together with glucosamine. preferable. Aspartame can be used as a sweetener, and sucrose fatty acid ester and calcium stearate can be used as a lubricant.

(c) Amino acids In the joint function improving composition of the present invention, in addition to glucosamine, active ingredients include alanine, asparagine, glutamic acid, histidine, isoleucine, leucine, phenylalanine, proline, serine, tyrosine, valine, and S-adenosylmethionine. It is preferable to use at least one type of amino acid (including salt) selected from the following. Examples of the salt include sodium salt, hydrochloride, and the like.
(d) Polyphenol In the joint function improving composition of the present invention, it is preferable to use at least one polyphenol selected from gallic acid and chlorogenic acid as an active ingredient together with glucosamine.

(e) Vitamins and minerals In the joint function improving composition of the present invention, in addition to glucosamine, active ingredients include vitamin A, vitamin B1, vitamin B2, vitamin B12, vitamin C, vitamin D3, sodium pantothenate, niacin, and biotin. It is preferable to use at least one vitamin/mineral selected from , vitamin K, β-carotene, calcium, and selenium. Note that calcium and selenium as minerals of the present invention include forms of compounds containing these metals.

(f) Cartilage component In the joint function improving composition of the present invention, it is preferable to use at least one cartilage component selected from proteoglycans and type II collagen as an active ingredient together with glucosamine.

Proteoglycans are complex polysaccharides in which glycosaminoglycans such as chondroitin sulfate and dermatan sulfate are covalently bonded to a protein core, and are present in large quantities in animal tissues, especially cartilage tissues. It is also known that proteoglycan exists in a living body in a structure in which a core protein is further bonded to hyaluronic acid, and its molecular weight is large, ranging from tens of thousands to tens of millions of millions. Specific examples of proteoglycans used in the present invention include animal-derived proteoglycans, and commercially available products can be used.

Type II collagen is collagen that is abundantly contained in cartilage, and for example, collagen extracted from cartilage of chickens, pigs, etc. can be used, and commercially available products can be used.

The joint function improving composition of the present invention can be used as a joint function improving agent having a cartilage protective effect, and the joint function improving agent contains glucosamine and other predetermined components, and is useful for improving joint function. There are no particular restrictions on the product as long as it can be distinguished from other products. For example, the scope of the present invention includes products in which a statement indicating that the product has a function of improving joint function on the main body, packaging, instruction manual, or advertising material of the present invention is included. For example, so-called health foods such as pharmaceuticals (including quasi-drugs), cosmetics, and functional foods whose efficacy has been approved by designated organizations such as foods for specified health uses, foods with nutritional function claims, and foods with functional claims. can be mentioned. So-called health foods include ``for knee and lower back problems'', ``for healthy walking'', ``for light movement'', ``adjusting joint function'', ``smoothing joint movement'', and ``improving joint function''. For example, the words "improve joint movement", "alleviate joint movement problems", "help joint movement", and "support joint movement" are displayed. The joint function improving composition of the present invention can be taken by anyone who is concerned about the above-mentioned effects regardless of gender or age; however, the joint function improving composition of the present invention can be taken more effectively. Therefore, it is desirable for healthy people excluding those with diseases to take it, and it is especially desirable for elderly people who have the above-mentioned problems to take it.

The joint function improving composition of the present invention can be used orally or externally. External preparations are not particularly limited as long as they are applied to the skin, scalp, etc., and their forms include ointments, creams, gels, lotions, emulsions, packs, poultices, etc. Forms such as external skin preparations and injections can be mentioned.

In addition, when the joint function improving composition of the present invention is used as an oral preparation, the forms include, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, and blocks. , solid preparations, pills, paste preparations, cream preparations, caplet preparations, gel preparations, chewable preparations, stick preparations, and the like. Among these, tablet, capsule, powder, granule, and liquid forms are particularly preferred. Specifically, supplements, packaged beverages filled in plastic bottles, cans, bottles, etc., instant powdered beverages and instant granular beverages that can be dissolved in water (hot water), milk, fruit juice, green juice, etc. can be exemplified. These are preferable because they are easy to drink during meals and can enhance palatability.

The content of glucosamine and other ingredients (active ingredients) in the joint function improving composition of the present invention may be appropriately contained within the range where the effects can be achieved.

Generally, when the joint function improving composition of the present invention is a drug or a supplement (tablet, capsule), the active ingredient may be contained in an amount of 0.01 to 100% by mass on a dry mass basis. The content is preferably 0.1 to 85% by mass, more preferably 0.5 to 70% by mass.

When the joint function improving composition of the present invention is a packaged beverage (liquid), it is preferable that the active ingredient is contained in an amount of 0.01 to 15% by mass, and preferably 0.03 to 12% by mass of the total in terms of dry mass. The content is more preferably .5% by mass, and even more preferably 0.05 to 10% by mass.

In addition, when the joint function improving composition of the present invention is an instant powder drink (powder) or instant granule drink (granules), the active ingredient is contained in an amount of 0.1 to 80% by mass of the total in terms of dry mass. The content is preferably 0.5 to 70% by mass, more preferably 1 to 60% by mass.

In order to more effectively exhibit the effects of the present invention, it is preferable that the active ingredient is contained in an amount of 80% by mass or more of the entire joint function improving composition of the present invention (excluding water) in terms of dry mass, and 90% by mass. % or more, more preferably 95% by mass or more, and particularly preferably 100% by mass. Further, when the joint function improving composition of the present invention contains any of the components (a) to (f), it is preferable that the contained components consist only of the active ingredients of the present invention. That is, when the joint function improving composition of the present invention contains component (a) (plant material), for example, it should be configured so that it does not contain plant materials other than barley, chomeiso, kudzu, rice, maqui berry, and ginger. is preferred.

There is no particular limit to the intake amount of the joint function improving composition of the present invention, but from the viewpoint of exhibiting the effects of the present invention more markedly, the intake amount of the active ingredient per day should be 500 mg/day or more. It is preferable to ingest it, more preferably at least 800 mg/day, even more preferably at least 1000 mg/day. The upper limit is not particularly limited, but is, for example, 5 g/day, preferably 4 g/day. The daily intake of glucosamine hydrochloride is preferably 500 to 4000 mg/day, more preferably 1000 to 3000 mg/day, and 1500 to 2500 mg/day. It is more preferable to take in an amount of 1,850 to 2,250 mg/day, and it is particularly preferable to take an amount of 1,850 to 2,250 mg/day.

The joint function improving composition of the present invention can be stored in one container or divided into, for example, 2 to 3 containers, so that the daily intake amount is the above-mentioned intake amount. can.

The blending mass ratio of glucosamine and other components is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1, in terms of dry mass. , more preferably in the range of 1:1 to 60:1, particularly preferably in the range of 1:1 to 50:1. When the blending ratio of glucosamine and other components is within the above range, the effects of the present invention can be more effectively exhibited.

The joint function improving composition of the present invention can be produced by a known method by adding ingredients other than the active ingredients that are acceptable as oral or external preparations, if necessary.

In addition, as the joint function improving composition as an oral preparation of the present invention, in addition to joint function improving compositions containing active ingredients, joint function improving compositions obtained by adding active ingredients to foods (joint function improving compositions) include joint function improving compositions containing active ingredients. For example, foods with increased content of the active ingredient of the present invention compared to normal foods (including natural foods), and foods that do not normally contain the active ingredient of the present invention. On the other hand, foods containing active ingredients can be mentioned. The active ingredients may be added separately, simultaneously, or together with other ingredients other than the active ingredients.

Examples of the joint function improving food of the present invention include drinks such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sorbet, and shaved ice; Noodles such as noodles and instant noodles; Confectionery such as candy, candies, gum, chocolate, tablets, snack foods, biscuits, jellies, jams, creams, baked goods, and bread; Fishery and livestock processed foods such as kamaboko, ham, and sausages. ; Dairy products such as processed milk, fermented milk, and yogurt; Oils and fats and processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing; Seasonings such as sauces and soy sauce; Curry, stew, and oyakodon Examples include retort pouch foods such as porridge, porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hashed rice, omelet rice, oden, marbodoff, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups. .

The joint function improving method of the present invention is characterized by ingesting the above-described joint function improving composition of the present invention, but does not include medical treatment. The joint function improving composition of the present invention is preferably ingested by healthy people excluding diseased people, and particularly preferably by elderly people who have the above-mentioned problems. Examples of the method of the present invention include a method of obtaining a joint function improving effect by providing the joint function improving food of the present invention in a restaurant or other eating establishment.

Hereinafter, the present invention will be explained based on examples.
[Example 1]
(1) Chondrocytes (NHAc-kn) were prepared in 10% FBS-DMEM to a concentration of 5×10 ⁴ cells/mL, and 200 μL of each was seeded onto a 96-well plate, resulting in a final concentration of 1×10 ⁴ cells. /well.
(2) After preculture for 1 to 2 days, samples were added as described below. The concentration of each sample was adjusted to 4 times the desired final concentration.

Note that samples insoluble in water (other components) were dissolved in DMSO and then adjusted to a 4-fold concentration sample in 1% DMSO-10% FBS-DMEM. Ca samples other than calcium chloride were dissolved in 1N HCl and then adjusted to a 4-fold concentration sample in 1/50N HCl-10% FBS-DMEM. The IL1b solution was prepared at a ratio of 2 μL of 10 μg/mL IL1b to 15 mL of 10% FBS-DMEM. In addition, as glucosamine, commercially available glucosamine hydrochloride was used.

(3) Approximately 18 hours after sample addition, cells were collected using CellAmp Direct RNA Prep Kit for RT-PCR (Takara). Thereafter, the expression level of MMP3 was measured using One Step SYBR (registered trademark) PrimeScript ^™ RT-PCR Kit II. Note that RPLP0 was also measured as an internal standard. In addition, when the expression level of MMP-3 is high, it indicates that the destruction of articular chondrocytes is progressing, and when the expression level of MMP-3 is low, the destruction of articular chondrocytes is suppressed, and the articular chondrocytes are protected. It is understood that

The results are shown in Tables 4 to 10 and FIGS. 1 to 13.

Each figure shows, from left to right, "control", "IL1b addition", "single addition of glucosamine (to IL1b addition)", "single addition of other components (to IL1b addition)", "glucosamine + other (to IL1b addition)" Component addition” results are shown. Further, the numerical value in the explanation at the bottom of the graph indicates the sample concentration; for example, "G_100" in the upper left graph of FIG. 1 indicates glucosamine 100 (μg/mL). The concentration unit of added components is μg/mL in all graphs.

For barley, dry and ground powder of young leaves was used.
For Chomeisou, a finely ground powder of fresh leaves was used.
For kudzu, a hot water extract (dry powder) of the flower was used.
As for rice bran, a commercially available product was used.
For Maqui berry, commercially available dry fruit powder was used.
For red ginger (Zingiber officinale var. Rubra), a hot water extract (dry powder) of the rhizome was used.
For ginger (Zingiber officinale), a hot water extract (dry powder) of the rhizome was used.
For lemon verbena, dried and crushed leaf powder was used.

As shown in Tables 4 to 10 and FIGS. 1 to 13, the combination of glucosamine and specific other components of the present invention synergistically reduced the expression level of MMP-3. Therefore, according to the joint function improving composition of the present invention, inflammation can be suppressed, and articular chondrocytes can be protected (destruction of articular chondrocytes can be suppressed), thereby making it possible to more effectively improve joint pain.

[Example 2] (Manufacture of tablets)
Tablets (6 tablets, 3000 mg) were produced containing the following ingredients.

Glucosamine hydrochloride 2000mg
Proteoglycan 5mg
Fossil coral Ca 150mg
Calcium stearate 50mg
β-carotene 10mg
Vitamin B1 5mg
Vitamin B2 5mg
Vitamin B12 5mg
Vitamin D3 2.5mg
Chomeisou end 300mg
Proline 30mg
Crystalline cellulose 50mg
Sucrose fatty acid ester 30mg
maltose remainder

The above tablets are taken in 6 tablets divided into 2 to 3 times a day and chewed, or taken without chewing with water.

[Example 3] (Manufacture of capsules)
The following mixture was encapsulated in soft capsules to produce 6 capsules.

Glucosamine hydrochloride 1500mg
Proteoglycan 5mg
Rice bran extract 20mg
Maqui berry powder 100mg
Shell fired Ca 120mg
Vitamin E 30mg
Niacin 5mg
Chlorogenic acid 10mg
Proline 20mg
Selenium 5mg
Sodium pantothenate 10mg
maltose remainder

The above tablets are taken in 6 tablets divided into 2 to 3 times a day with water.

[Example 4] (Manufacture of granules)
Granules (3000 mg) were prepared by mixing the following ingredients in a conventional manner.

Glucosamine hydrochloride 1800mg
Proteoglycan 5mg
Seashell unfired Ca 200mg
Sucrose fatty acid ester 50mg
Selenium 5mg
Vitamin E 50mg
Barley grass powder 800mg
Niacin 10mg
Biotin 10mg
Proline 5mg
starch remainder

[Example 5] (Production of instant powder)
An instant powder (6 g) was prepared by mixing the following ingredients in a conventional manner.

Glucosamine hydrochloride 2500mg
Proteoglycan 5mg
Seashell unfired Ca 200mg
Barley grass powder 1000mg
Chomeisou end 500mg
Ginger powder 250mg
Selenium 5mg
Vitamin E 300mg
Vitamin K 200mg
Niacin 50mg
Biotin 50mg
Proline 30mg
Valine 30mg
Leucine 20mg
Isoleucine 20mg
Aspartame 300mg
Oligosaccharide 500mg
Dextrin remainder

[Example 6] (Production of liquid agent)
A liquid preparation (50 mL) consisting of the following components was produced.

Glucosamine hydrochloride 2000mg
Type II collagen 25mg
Milk Ca 200mg
Aspartame 800mg
Red ginger extract 300mg
Ginger extract 200mg
Kudzu flower extract 150mg
Proline 100mg
Asparagine 50mg
Valine 25mg
Leucine 20mg
Isoleucine 20mg
Gallic acid 10mg
Vitamin C 5mg
Fragrance (appropriate amount) Water (Remainder)

The composition of the present invention has a high joint function improving effect and can be used as an oral preparation or an external preparation, and therefore the industrial utility of the present invention is high.

Claims (1)

An oral composition for improving joint function containing glucosamine as an active ingredient for improving joint function and further containing chlorogenic acid (excluding (1) and (2) below).
(1) Contains glucosamines, carotenoids and/or eicosapentaenoic acid (EPA), and the carotenoids include fucoxanthin, lutein, astaxanthin, zeaxanthin, β-carotene, α-carotene, and β-cryptoxanthin. An arthritis-improving composition (2) A sweetener composition comprising glucosamine, a high-intensity sweetener, and a sweet taste-improving composition), characterized in that the composition is one or a combination of two or more selected from the group consisting of: